Laboratorios Farmaceuticos Rovi (FRA:41L) Moat Score: 0/10 (As of Jul. 05, 2026)


FRA:41L Laboratorios Farmaceuticos Rovi SA FRA:41L
93 GF Score
Price €57.90
GF Value €51.89
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is Laboratorios Farmaceuticos Rovi Moat Score?

Laboratorios Farmaceuticos Rovi has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Laboratorios Farmaceuticos Rovi has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Laboratorios Farmaceuticos Rovi might have No Moat - No discernible moat.

Laboratorios Farmaceuticos Rovi  (FRA:41L) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Laboratorios Farmaceuticos Rovi Moat Score Related Terms

FRA:41L
93GF Score
Laboratorios Farmaceuticos Rovi SA FRA:41L
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Laboratorios Farmaceuticos Rovi (FRA:41L) Overvalued in 2026?

Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be overvalued. The current stock price of €57.90 is trading 11.6% above its estimated GF Value™ of €51.89. GuruFocus considers Laboratorios Farmaceuticos Rovi to be Modestly Overvalued.

Key valuation signals for FRA:41L:

  • Moat Score: 0
  • GF Value™: €51.89 vs. price of €57.90 (11.6% above fair value)
  • GF Score™: 93/100 with 1 warning sign

No single metric tells the full story. See the FRA:41L stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Laboratorios Farmaceuticos Rovi Business Description

Address Julian Camarillo, 35, Madrid, ESP, 28037
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
93GF Score

Get the complete analysis for FRA:41L

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€57.90
Price
€51.89
GF Value